by Pulmonary edema therapeutics refer to drugs or medications used for treating excess fluid accumulation in the lung tissues and air spaces. The main types of drugs used are diuretics, vasodilators, inotropic agents, antimicrobials, and others. Pulmonary edema occurs mostly in conditions like heart failure, lung injuries, drowning, near drowning, etc. It leads to impaired gas exchange and shortage of oxygen in blood. Increasing incidence of respiratory diseases like COPD, asthma, pneumonia, lung cancer is driving the demand for pulmonary edema therapeutics.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing incidence of respiratory diseases is one of the major trends fueling the growth of the pulmonary edema therapeutics market. Respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), pneumonia are rising globally due to growing pollution levels, rising cigarette smoking, aging population, etc. As per the Global Burden of Disease Study 2019, COPD is projected to be the third leading cause of death worldwide by 2030. Rising cases of respiratory diseases increase the risk of pulmonary edema, thereby driving the need for appropriate treatment medications and drugs. Innovation of novel and targeted drugs and combination therapies by market players is another key trend witnessed in the market.
Segment Analysis
The global pulmonary edema therapeutics market is segmented on the basis of type, treatment, route of administration, end-user and distribution channel. On the basis of type, it is segmented into acute pulmonary edema and chronic pulmonary edema. Acute pulmonary edema is expected to dominate the market over the forecast period as it occurs more frequently as compared to chronic pulmonary edema. On the basis of treatment, it is segmented into diuretics, oxygen therapy, vasodilators andothers. Diuretics are expected to dominate the market due to ease of administration and effectiveness in reducing fluid overload from tissues including the lungs.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market Demand is expected to witness high growth over the forecast period. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.
Regional analysis
North America is expected to dominate the pulmonary edema therapeutics market over the forecast period owing to higher prevalence of pulmonary edema and growing aged population. Furthermore, developed healthcare infrastructure and availability of advanced treatment options also contribute to its large share in the market. Asia Pacific is expected to witness fastest growth in the market during the forecast period due to increasing healthcare expenditure and growing awareness about pulmonary diseases.
Key players
Key players operating in the pulmonary edema therapeutics market are Crayola LLC, Faber-Castell AG, and Reeves (Colart Group). Crayola LLC offers a wide range of products for pulmonary edema treatment such as diuretics and oxygen therapy equipment. Similarly, Faber-Castell AG provides vasodilators whereas Reeves (Colart Group) offers pain relieving medications and other supportive treatments.
